Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Last trade$8.65
Day change-$0.085 (-0.97%)
Day range$8.59 – $8.73
Volume399,926
Market cap$5.94B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for GRFS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for GRFS.
Recent news
Company coverage with links to the original publishers.
The European human biospecimen market is projected to grow at an 8.24% CAGR from $881.8 million in 2025 to $1.94 billion by 2035, driven by increasing demand for precision medicine, oncology research, and expanding biobanks. Growth is supported by rising pharmaceutical R&D spending and EU-funded initiatives, though challenges include stringent GDPR regulations, high operational costs, and variability in consent frameworks across countries.
The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.
The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.
The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.
Canadian health care advocates are calling for the closure of Grifols plasma collection facilities and a public takeover following two deaths in Winnipeg linked to plasma sales, a third lawsuit for kidney damage, and Health Canada reports of non-compliance at four additional Grifols sites.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.1686 per share
Declared
Nov 3, 2026
Ex-dividend
Dec 3, 2026
Pay date
Dec 11, 2026
Ex-dividend
Amount / share
Pay date
Type
Jul 2, 2026
$0.1058
Jul 9, 2026
irregular
Aug 12, 2025
$0.1758
Aug 20, 2025
irregular
Jun 3, 2021
$0.4566
Jun 14, 2021
recurring
Oct 30, 2020
$0.2014
Nov 9, 2020
unknown
Dec 2, 2019
$0.2219
Dec 11, 2019
recurring
Stock splits
Historical share-structure events and their execution dates.